acquired
Stage
2002
Founded
1
Investors
About
Intercept Pharmaceuticals develops and commercializes therapeutics targeting chronic liver diseases through proprietary bile acid chemistry, with a focus on rare and serious liver conditions such as primary biliary cholangitis.
Explore Intercept Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.